Pagoclone doesn't seem to be working out, but with trospium, Indevus may have a one more shot at comeback.

FORBES: A Biotech Phoenix Could Be Rising

In June, Pfizer (nyse: PFE - news - people ) ended its collaboration with Indevus over an anti-anxiety drug called pagoclone.

FORBES: Magazine Article

It began licensing compounds like pagoclone and trospium, which is licensed from Europe's Madaus AG , in the hopes that one of them would make it through the FDA's goalposts.

FORBES: A Biotech Phoenix Could Be Rising

In August, Aventis (nyse: AVE - news - people ), which had originally developed pagoclone and had licensed it to Indevus, decided not to exercise its option to develop the drug.

FORBES: Magazine Article